Kostenrelevanz und Einsparpotentiale

  • P. E. Valk


Die Kosteneffektivität einer diagnostischen oder therapeutischen Prozedur ist am häufigsten beschrieben worden als die Kosteneffektivitätsratio, die sich ergibt aus der Nettozuwachsrate an Kosten dividiert durch die Nettozuwachsrate an Effektivität durch die Anwendung der Methode.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abella-Columna E, Valk PE, Pounds TR, Wolkov HB, Liebenhaut MH, Haseman MK, Lutrin CL (1996) Staging Hodgkin’s disease by whole-body PET-FDG imaging. J Nucl Med 37: 139PGoogle Scholar
  2. Abella-Columna E, Manolidis S, Isaacs RS, Pounds TR, Donald PJ, Valk PE (1997) Staging recurrent head and neck cancer by whole-body FDG PET imaging. J Nucl Med 38: 155PGoogle Scholar
  3. Pounds TR, Valk PE, Spitler L, Haseman MK, Myers RW, Lutrin CL (1995) Whole-body PET-FDG imaging in diagnosis of metastatic melanoma: comparison to CT. J Nucl Med 36: 116PGoogle Scholar
  4. Steele GJ, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D (1991) A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: gastrointestinal tumor study group protocol 6584. J Clin Oncol 9: 1105–1112PubMedGoogle Scholar
  5. Valk PE, Pounds TR, Hopkins DM et al. (1995) Staging non-small-cell lung cancer by whole-body PET imaging. Ann Thor Surg 60: 1573–1582CrossRefGoogle Scholar
  6. Valk PE, Abella-Columna E, Tesar RD, Pounds TR, Haseman MK, Myers RW (1996) Diagnostic accuracy and cost-effectiveness of whole-body PET-FDG imaging in recurrent colorectal cancer. J Nucl Med 37: 132PGoogle Scholar
  7. Valk PE, Segall GM, Johnson DL, Pounds TR, Tesar RD, Jadvar H, Abella-Columna E (1997) Cost-effectiveness of whole-body FDG PET imaging in metastatic melanoma. J Nucl Med 38: 90PGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • P. E. Valk

There are no affiliations available

Personalised recommendations